Sector News

ConvaTec buys US catheter distributor J&R Medical

March 5, 2018
Life sciences

ConvaTec Group PLC said Friday it acquired US-based catheter supplies distributor J&R Medical LLC for an undisclosed sum.

ConvaTec – a FTSE 250-listed medical technology firm – said J&R will join its Home Distribution unit. In 2017, J&R generated USD9.0 million in revenue. Over the same period, ConvaTec generated USD164.0 million pretax profit on revenue of USD1.76 billion.

ConvaTec also announced it had sold its respiratory delivery business in US states Arizona and Utah. Financial details of these divestments were also not disclosed.

The combination of both the acquisition and sales will be positive to revenue and earnings before interest, taxes, depreciation and amortisation, Convatec explained.

“The addition of J&R Medical to our Home Distribution Group will strengthen our presence in a substantial and important US market,” ConvaTec Chief Executive Officer Paul Moraviec said. “The acquisition also reinforces ConvaTec’s position as a leading distributor of urinary catheters in the US.”

Shares in ConvaTec were 0.3% lower at 205.10 pence in early trading Friday.

By Ahren Lester

Source: Alliance News via Interactive Investor

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend